
### [MONDO:0018266](http://purl.obolibrary.org/obo/MONDO_0018266)
**Label:** ataxia-telangiectasia variant

**Subclasses:** [MONDO:0008840](http://purl.obolibrary.org/obo/MONDO_0008840) (ataxia telangiectasia), [MONDO:0008841](http://purl.obolibrary.org/obo/MONDO_0008841) (ataxia-telangiectasia with generalized skin pigmentation and early death), 

**Mapped go classes:** [GO:0016569](http://purl.obolibrary.org/obo/GO_0016569) (covalent chromatin modification), [GO:0006281](http://purl.obolibrary.org/obo/GO_0006281) (DNA repair), [GO:0000723](http://purl.obolibrary.org/obo/GO_0000723) (telomere maintenance), [GO:0004672](http://purl.obolibrary.org/obo/GO_0004672) (protein kinase activity), [GO:0008630](http://purl.obolibrary.org/obo/GO_0008630) (intrinsic apoptotic signaling pathway in response to DNA damage), [GO:0005694](http://purl.obolibrary.org/obo/GO_0005694) (chromosome), [GO:0006974](http://purl.obolibrary.org/obo/GO_0006974) (cellular response to DNA damage stimulus), [GO:0004674](http://purl.obolibrary.org/obo/GO_0004674) (protein serine/threonine kinase activity), [GO:0006975](http://purl.obolibrary.org/obo/GO_0006975) (DNA damage induced protein phosphorylation), [GO:0006302](http://purl.obolibrary.org/obo/GO_0006302) (double-strand break repair), [GO:0000166](http://purl.obolibrary.org/obo/GO_0000166) (nucleotide binding), [GO:0000077](http://purl.obolibrary.org/obo/GO_0000077) (DNA damage checkpoint), [GO:0005634](http://purl.obolibrary.org/obo/GO_0005634) (nucleus), [GO:0005524](http://purl.obolibrary.org/obo/GO_0005524) (ATP binding), [GO:0000781](http://purl.obolibrary.org/obo/GO_0000781) (chromosome, telomeric region), [GO:0042162](http://purl.obolibrary.org/obo/GO_0042162) (telomeric DNA binding), [GO:0005739](http://purl.obolibrary.org/obo/GO_0005739) (mitochondrion), [GO:0016572](http://purl.obolibrary.org/obo/GO_0016572) (histone phosphorylation), [GO:0016310](http://purl.obolibrary.org/obo/GO_0016310) (phosphorylation), [GO:0016740](http://purl.obolibrary.org/obo/GO_0016740) (transferase activity), [GO:0016301](http://purl.obolibrary.org/obo/GO_0016301) (kinase activity), [GO:0010389](http://purl.obolibrary.org/obo/GO_0010389) (regulation of G2/M transition of mitotic cell cycle), 

**Class expressions from DL-Learner:**

- [GO:0006975](http://purl.obolibrary.org/obo/GO_0006975) (DNA damage induced protein phosphorylation) 75.00%
- [GO:0005524](http://purl.obolibrary.org/obo/GO_0005524) (ATP binding) 75.00%
- [GO:0032559](http://purl.obolibrary.org/obo/GO_0032559) (adenyl ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 75.00%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 75.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 75.00%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0097367](http://purl.obolibrary.org/obo/GO_0097367) (carbohydrate derivative binding) 75.00%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0032555](http://purl.obolibrary.org/obo/GO_0032555) (purine ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 75.00%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0032553](http://purl.obolibrary.org/obo/GO_0032553) (ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 75.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0097367](http://purl.obolibrary.org/obo/GO_0097367) (carbohydrate derivative binding) 75.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0036094](http://purl.obolibrary.org/obo/GO_0036094) (small molecule binding) 75.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032559](http://purl.obolibrary.org/obo/GO_0032559) (adenyl ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 75.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032555](http://purl.obolibrary.org/obo/GO_0032555) (purine ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 75.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032553](http://purl.obolibrary.org/obo/GO_0032553) (ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 75.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 75.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0017076](http://purl.obolibrary.org/obo/GO_0017076) (purine nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 75.00%


